Kornimate/medical-research-clean huggingface dataset:
continuous tremor assessment during daily activities

Conditions: Essential Tremor

Summary: the specific aim of this study is to evaluate if tremor severity and quality of life can be improved more using continuous home monitoring along with traditional assessments versus traditional assessments alone.


Eligibility criteria:
inclusion criteria: * diagnosed with essential tremor * currently taking medication to control tremor exclusion criteria: * cognitive limitations that prevent comprehension or execution of study protocol
comparison of ultrasound-guided steroid injection and dry needling in piriformis muscle syndrome

Conditions: Piriformis Muscle Syndrome

Summary: the aim of this study is to to compare its effectiveness ultrasound-guided steroid injection, dry needling treatments and exercises in patients diagnosed with piriformis syndrome.

piriformis syndrome is a painful entrapment neuropathy caused by compression of the sciatic nerve under the piriformis muscle. the most common cause is myofascial pain syndrome. there is no gold standard treatment for piriformis syndrome. the main purpose of treatment methods is to reduce local pain, muscle tension and spasm. this work; it will contribute to the literature by comparing steroid, dry needling and exercise treatments in patients with piriformis syndrome.

Eligibility criteria:
inclusion criteria: 1. age between 18-60, 2. hip pain for ≥1 month 3. local piriformis pain with prolonged sitting (\>20 minutes) and increased sensitivity 4. patients with suspected piriformis syndrome based on clinical maneuvers 5. signing and informed consent from showing consent to participate in the study exclusion criteria: 1. hip surgery 2. lumbar disc disease 3. history of inflammatory hip disease 4. medical treatment for pain is started 5. neurological deficit 6. breastfeeding or pregnant 7. allergy to local anesthetic 8. use of anticoagulants 9. body mass index \>35 10. active psychiatric illness 11. uncontrolled hypertension and diabetes mellitus disease 12. noncompensated chronic lung/heart/renal failure 13. history of vascular/tumoral disease

Keywords: piriformis syndrome steroid injection dry needling exercise
sars cov_2 incidence of healthy health workers

Conditions: SARS COV-2 IgG Levels on Health Workers

Summary: since the severe acute respiratory syndrome coronavirus-2 (sars-cov-2) first emerged in wuhan, china, on 12 december 2019, it has spread rapidly across the world and developed into a pandemic. the pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of covid-19. the rapid spread of sars-cov-2 has caused considerable harm to public health and the economy. alongside other laboratory tests and clinical findings of the covid-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. the determination of antibodies enables confirmation of the sars-cov-2 infection in asymptomatic patients in addition to those with typical symptoms. in this study, we aimed to determine the sars-cov-2 seroprevalence and the igg antibody levels among healthcare workers who frequently encountered covid-19 patients in our hospital.


Eligibility criteria:
inclusion criteria: healthy health workers - sars cov-2 pcr (-) exclusion criteria: health workers - sars cov-2 pcr (+) pregnancy autoimmune diseases received immunosuppressive therapy
a clinical trial to test the saftey and success rate for a cerrumen cleaning device - "wondertip".

Conditions: External Ear Disorder

Summary: wondertip is a silicone single use device with a coil end, designed for the purpose of evacuating impacted cerumen of external ear canals. this trial aims at testing the safety and efficacy of this device. the participating investigators will be ent doctors with the skill of examining the treating ear problems.

cerumen is ear wax, a combination of dead skin cells of the external ear canal, sebaceous glands secretions and ceruminous sweat glands secretions. cerumen exists in a range of people but sometimes it become an obstacle to patients or caregivers. cerumen may accumulate in the external ear canal and cause discomfort to the patient, sensation ofobtuseness and conductive hearing loss. patients who use hearing aids may suffer from problems wearing them, and sometimes the cerumen may plug the inner part of the hearing aid or the ventilation channel of the ear phone. for caregivers, cerumen may poses a diagnostic challenge, by concealing part of the external ear canal and tympanic membrane, thus making it difficult to observe the middle ear. cerumen my affect the results of audiometric tests, abr tests, otoacustic emission tests and in conducting tympanometric tests. all of which may result in false results. the incidence of cerumen is estimated to be betwean 7 to 35% of the general population. there are few options to evacuate the cerumen, but they usually require skill and the use of otology microscope. it mays casue discomfort or pain, and even trauma to the external ear canal or the tympanic membrane. a device which does not require a special skill or equipment may have a advantage, especially for the general practioner doctor. the wondertip is an israeli patent, made of silicone with a coil like end, targeted to evacuate the cerumen in a safe and effective manner. the coil is gently inserted to the ear canal, grasps and evacuates the cerumen. the purpose of the trial is to investigate the safety and efficacy of the wondertip. a second purpose is to messure external ear canal depth. each candidate which will present with cerumen impaction will recieve a detailed explanation regarding the trial. if the patient agrees, and signs a concent form, a short interview will take place by the doctor. an evacuation of the cerumen will be attempted by the same doctor with the wondertip. further the doctor will document details regarding the safety and efficacy of the procedure.

Eligibility criteria:
inclusion criteria: * patients over 1 year old who have cerumen impaction. exclusion criteria: * external ear infection * chronic otitis media with perforation of the tympanic membrane * past ear surgery * otorrhea * inflamation of the auricle or the periauricular region * temporal bone neoplasm * deafness in the contralateral ear (single sided deafness).
short term outcomes of primary percutaneous coronary intervention (pci) patients presented with acute heart failure in assuit university heart hospital

Conditions: Primary Percutaneous Coronary Intervention

Summary: observational study outcome of pci in patients presented with acute heart failure


Eligibility criteria:
inclusion criteria: * age more than 18 years * acute heart failure * pci exclusion criteria: * nstemi * end stage renal disease
evaluate the safety and pharmacokinetic profile of cpl-01 in the management of acute postoperative pain

Conditions: Abdominoplasty

Summary: evaluate the safety and pharmacokinetic profile of cpl-01 in patients after mini-abdominoplasty

this is a randomized, double-blind, study to evaluate the safety, pk profile of cpl-01 for the management of postoperative pain after mini-abdominoplasty surgery.

Eligibility criteria:
inclusion criteria: * subject provides signed, written informed consent before participation in the study. * subject is aged ≥18 and ≤70 years at the time of informed consent and is male or female. * subject is scheduled to undergo elective mini-abdominoplasty surgery under general anesthesia without collateral procedures. * female subjects are eligible only if all the following apply: 1. not pregnant 2. not breastfeeding 3. not planning to become pregnant during participation in the study 4. committed to the use of an acceptable form of birth control for the duration of the study until at least 30 days after administration of ip. * male subjects must commit to the use of a reliable method of birth control for the duration of the study until at least 30 days after administration of ip or be surgically sterile (biologically or surgically). * subject is free of any physical, mental, or medical conditions which, in the opinion of the investigator, make mini-abdominoplasty or study participation inadvisable. exclusion criteria: * subject has known, suspected, or reported history of alcohol or drug abuse or dependence within the previous 2 years as assessed by the investigator * subject has impaired liver function (e.g., aspartate aminotransferase/alanine aminotransferase greater than 3 times the upper limit of the reference range, bilirubin greater than 1.5 times the upper limit of the reference range unless due to gilbert's syndrome, active hepatic disease, evidence of clinically significant liver disease, or other condition such as alcoholism, cirrhosis, or hepatitis, etc.) that suggests the potential for an increased susceptibility to hepatic toxicity with ip exposure. * subject has clinically significant renal abnormalities (creatinine ≥1.5 × upper limit of normal). * subject has hemoglobin a1c ≥7.0%. * subject has participated in another clinical study and/or received an ip (marketed or premarket) within 30 days before surgery. * subject has a history of, or positive test results for, human immunodeficiency virus, hepatitis b surface antigen, or hepatitis c virus antibody at screening. * subject with an upper respiratory infection/cough in the 14 days before surgery. * subjects with a history of significant postoperative nausea and vomiting.
plaque regression with cholesterol absorption inhibitor or synthesis inhibitor evaluated by intravascular ultrasound

Conditions: Hypercholesterolemia; Coronary Artery Disease

Summary: the purpose of this study was to evaluate the difference in the effect of coronary plaque regression (as measured by intravascular ultrasound \[ivus\] imaging) between cholesterol absorption inhibitor and cholesterol synthesis inhibitor.


Eligibility criteria:
inclusion criteria: * signed written informed consent, * 30 to 85 years old, * plan to undergo pci and ldl-c \>= 100 mg/dl exclusion criteria: * familial hypercholesterolemia * being treated with zetia (ezetimibe) * being treated with fibrates * renal insufficiency (serum creatinine \>= 2.0 mg/dl) * altered hepatic function (serum aspartate aminotransferase or alanine aminotransferase \>= 3-folds of standard value in each institute) * undergoing hemodialysis or peritoneal dialysis * allergic to lipitor and/or zetia * severe underlying disease * lack of decision-making capacity * recognized as inadequate by attending doctor

Keywords: heart diseases hyperlipidemia atorvastatin ezetimibe cardiovascular diseases hypercholesterolemia coronary artery disease dyslipidemias intravascular ultrasound
atareal (antihistamine treatment for allergic rhinitis in real life)

Conditions: Rhinitis, Allergic, Perennial

Summary: comparison of clinical efficacy and safety of levocetirizine in per continuous versus on demand, measured by evolution of individual symptom scores during 6 months.


Eligibility criteria:
inclusion criteria: * clinical history of persistent allergic rhinitis (per) requiring treatment known at least since 2 years. * positive skin prick test (wheal \> 3 mm larger than the diluent control) or radio allergo sorbent assay (rast) (\>= 3.5 iu/ml) to house dust mite (hdm) and parietaria (less than 1 year). * minimum mean total 4 symptom score (t4ss) of 6 over baseline period. exclusion criteria: * subjects currently treated by specific parietaria pollen immunotherapy * subjects suffering from non-allergic asthma * chronic use of inhaled steroids and/or long acting β2 agonists; and/or corticosteroids dependent asthma (severe asthma) * atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids

Keywords: persistent allergic rhinitis hdm parietaria sneezing rhinorrhea ocular pruritus rhinasthma inflammatory cells icam-1 atareal xyzal levocetirizine
effect of lidocaine on postoperative pain in elderlypatients undergoing colorectal cancer surgery

Conditions: Colorectal Cancer

Summary: patients who meet the enrollment criteria will be randomized 1:1 to the lidocaine group or placebo group.

patients who meet the enrollment criteria will be randomized 1:1 to the lidocaine group or placebo group. in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.in the placebo group, the same volume of normal saline will be administered during anesthesia. the postoperative pcia device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 ml in 0.9% normal saline solution with a total volume of 200 ml.

Eligibility criteria:
inclusion criteria: 1. participants were at least 60 years old; 2. american society of anesthesiologists (asa) physical status i to iii; 3. body-mass index of 18-30 kg/m2; 4. scheduled for elective colorectal surgery. exclusion criteria: 1. metastases occurring in other distant organs; 2. severe hepatic insufficiency (aspartate aminotransferase or alanine transaminase or bilirubin \>2.5 times the upper limit of normal); 3. renal impairment (creatinine clearance \<60 ml/min); 4. cardiac rhythm disorders or systolic heart failure (second-and third-degree heart block, ejection fraction \<50%); 5. allergies to any of the trial drugs; chronic opioid use; 6. inability to comprehend numeric rating scale.
valid: study to compare the reduction of predialysis systolic blood pressure with valsartan compared to irbesartan in patients with mild to moderate hypertension on long-term hemodialysis

Conditions: Hypertension

Summary: the purpose of the study is to compare the efficacy, safety and tolerability of valsartan 80 mg (with a starting dose of 40 mg) to irbesartan 150 mg (with a starting dose of 75 mg) in patients on long-term haemodialysis with mild to moderate increased mean supine systolic blood pressure (mssbp).


Eligibility criteria:
inclusion criteria: * patients with mild and moderate hypertension defined by a mssbp ≥ 140 mmhg and \< 180 mmhg at visits 1 and 2 for treated and untreated patients * chronic hemodialysis for at least 6 months prior to visit 1 as substitution therapy. * if treated with epoetin: patients with a stable hematocrit ≤ 40% (± 5%). exclusion criteria: * inability to discontinue angiotensin ii receptor blockers (arbs) safely for a period of 1 week, as required by the protocol. * treatment with more than 3 different compounds for the treatment of hypertension at visit 1. * atrial fibrillation other protocol-defined exclusion criteria may apply.

Keywords: hypertension valsartan dialysis renal disease
a study of the effect of food on the pharmacokinetics of single dose ro5185426 and the safety and efficacy of continuous administration in patients with braf v600e mutation-positive metastatic melanoma

Conditions: Malignant Melanoma

Summary: this randomized, open-label, two period crossover study will evaluate the effect of food on the pharmacokinetics of a single dose of ro5185426 and the efficacy and safety of continuous administration in patients with braf v600e mutation-positive metastatic melanoma. patients will be randomized to receive in a crossover design single oral doses of ro5185426 with or without food, with a 10-day washout period between doses. following the crossover periods, patients will receive ro5185426 orally twice daily on a continuous basis until disease progression or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * histologically confirmed metastatic melanoma (stage iv, american joint committee on cancer) * positive braf v600e mutation result determined by cobas 4800 braf v600 mutation test * previously treated patients must have failed at least one prior treatment regimen; if patients have received prior systemic treatments for metastatic melanoma, the time elapsed from previous therapy must be \>/= 28 days; patients must have recovered fully from toxicities of all prior therapy * eastern cooperative oncology group (ecog) performance status 0 or 1 * evaluable disease (measurable for disease progression according to recist criteria) * adequate hematological, renal and liver function exclusion criteria: * active cns lesions * history of or known spinal cord compression or carcinomatous meningitis * anticipated or ongoing administration of anti-cancer therapies other than those administered in this study * previous malignancy within the past 5 years except for basal or squamous cell carcinoma of the skin, melanoma in-situ and carcinoma in-situ of the cervix * previous treatment with braf inhibitor (sorafenib allowed) or mek inhibitor * refractory nausea or vomiting, malabsorption, external biliary shunt, or history of any type of gastrointestinal surgery that would preclude adequate absorption of study drug
predicting steroid dependent liver injury with polyreactive immunoglobulin g

Conditions: Autoimmune Hepatitis; Autoimmune Liver Disease

Summary: the investigators identified polyreactive immunoglobulin g (pigg) in adults (published in hepatology: https://doi.org/10.1002/hep.32134) and children (in preparation). quantification of these pigg using a "home-made" elisa facilitates the diagnosis of autoimmune hepatitis (aih) as compared to non-aih liver diseases and healthy controls. positivity for pigg was independent from ana/sma positivity and equally diagnostic for aih even when conventional autoantibodies (ana/sma/sla/lkm) were negative. additionally, the frequency of pigg was lower than conventional autoantibodies (ana, sma) in vaccinia/drug associated severe liver injury in a retrospective multicenter study after covid-19 vaccination (https://doi.org/10.1016/j.jhepr.2022.100605). aims of the study the study aims to evaluate the diagnostic capacity of pigg to predict aih in comparison to other liver diseases prospectively. to avoid diagnostic inaccuracy between aih with long-term need for an immunosuppression and drug induced liver injury with autoimmune features, which can be indistinguishable from aih at baseline and which has a very low relapse rate after a short steroid course, a follow-up after six months is obligatory for inclusion. therefore, the investigators will collect one serum sample from every patient (without immunosuppressive treatment) that presents to the respective hospital for evaluation of liver disease by liver biopsy within one year after initiation of the study and that provided written informed consent. follow-up for evaluation of steroid dependency at six months after diagnosis is obligatory.


Eligibility criteria:
inclusion criteria: * diagnostic liver biopsy for the work-up of any liver disease * informed consent * definition of any liver disease according to current societal guidelines exclusion criteria: * no ongoing immunosuppression at the liver biopsy or prior to the liver biopsy * liver biopsies for the grading or staging of an already known liver disease (e.g. non-alcoholic fatty liver disease (nafld), hepatitis b/d virus infections (hbv/hdv infection), ...)
multicenter aids cohort study (macs)

Conditions: HIV Infections

Summary: this is a comprehensive observational study of hiv infection in homosexual and bisexual men.

the multicenter aids cohort study (macs) provides important information about the changing nature of hiv-mediated disease progression, the impact of antiretroviral treatment, the nature of hiv pathogenesis, and viral and host genetic factors. this study will also assess the long-term patterns of therapy use and risk-taking behaviors. patients will have study visits every 6 months. the visits will include interviews, specimen collection, and a physical examination.

Eligibility criteria:
inclusion criteria: * hiv negative, or * hiv positive and no history or current use of highly active antiretroviral therapy (haart), or * hiv positive haart recipient with documentation of haart initiation, no aids diagnosis prior to haart initiation, and a cd4 cell count and hiv-1 rna measurement within 6 months prior to first haart use. * sexual intercourse with men or at least 5 male or female partners in the 5 years prior to enrollment. exclusion criteria: * injection drug use within 1 year of enrollment. * perinatally acquired hiv infection.
associative memory in adults with an autism spectrum disorder

Conditions: Autistic Disorder

Summary: the objective of this multidisciplinary project is to explore the deficit of associative memory in asd (autistic spectrum disorder) that could result from abnormal brain connectivity. the hypothesis of abnormal functioning of the fronto-hippocampal network has been evocated but has never been tested. hence, the present project will include two complementary assessments conducted on a group of adults aged from 18 to 30 with asd compared to a control group matched in chronological age and intellectual quotient. the first assessment is devoted to the study of associative memory and its eeg correlates and the second focused on the investigation of perceptual strategies related to associative memory using the technique of eye-tracking. both behavioral and imaging data would provide new insights on the relationship between perception and memory in asd.


Eligibility criteria:
inclusion criteria: * adult between 18 and 30 years old * right handed * affiliated to the french national health care system * asd only for the group of patients exclusion criteria : * mental retardation * schizophrenia * adhd * brain injury with lost of consciousness * neurological disease
genes, proteins, and metabolites in drug-resistant epilepsy (dre) patients

Conditions: Drug Resistant Epilepsy; Traumatic Brain Injury Without Open Intracranial Wound

Summary: in patients with drug-resistant epilepsy (dre), there may be changes at the genetic, proteomic, and metabolomic levels when comparing epileptic tissues from dre to normal tissues in traumatic brain injury (tbi). these changes could help in understanding the pathophysiological mechanisms of epilepsy and in identifying new therapeutic targets.

genomical studies have identified changes in the expression of certain genes within epileptic tissues. these genes may be involved in pathways related to the balance of neuronal excitability and inhibition, synaptic transmission, and cell apoptosis. proteomic studies will reveal changes in the abundance and modifications of proteins in epileptic tissues. these could involve proteins related to the control of neuronal excitability and synaptic transmission, such as ion channels, neurotransmitter receptors, and synaptic proteins. metabolomic researches will reveal changes in metabolites within epileptic tissues. epilepsy may lead to disruptions in metabolic pathways, affecting key processes such as energy metabolism, amino acid metabolism, and lipid metabolism. sample size: there is no minimum or maximum, but is expected to be far less than 10. in summary, patients with drug-resistant epilepsy might have changes in genes, proteomics, and metabolomics within epileptic tissues compared to normal tissue from tbi. further research into these changes will deepen our understanding of the pathophysiology of epilepsy and guide the need for new treatment strategies.

Eligibility criteria:
inclusion criteria: 1. 14-60 years old, male or female, han chinese; 2. drug-resistant epilepsy; 3. required surgical implantation of seeg electrodes. exclusion criteria: 1. progressive encephalopathy or progressive structural damage in the central nervous system; 2. significant heart, liver, renal insufficiency, and other medical diseases; 3. severe side effects from taking antiepileptic drugs at the time of enrollment and not inappropriate for seeg; 4. significant intellectual disability; 5. a history of alcohol and drug abuse; 6. any contraindication to mri.

Keywords: genomics proteomics metabolomics drug resistant epilepsy traumatic brain injury